Navigation Links
Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
Date:11/10/2008

ons - 2007

Pre- Income Diluted Pre- Income Diluted

tax Taxes EPS tax Taxes EPS

Year-to-Date

Income from continuing

operations - GAAP $92.3 $25.2 $1.07 $106.2 $35.8 $1.13

Adjustments:

Antitrust litigation - - - 1.2 0.4 0.01

Special charges 22.8 8.9 0.22 (1.4) (0.3) (0.02)

Stock modification charge 5.8 2.1 0.06 - - -

Loss on extinguishment of

debt 3.2 1.2 0.03 - - -

Separation costs 1.6 0.4 0.02 0.6 0.1 0.01

Income from continuing

operations - Adjusted $125.7 $37.8 $1.40 $106.6 $36.0 $1.13

Note: Certain per share amounts may not accurately add due to rounding.

Note: Earnings in the above presentation of adjusted income from

continuing operations have not been adjusted to remove the effects of

discrete period tax adjustments recognized in any of the periods

presented. Discrete period tax adjustments are routinely recognized

throughout any given year under a variety of circumstances and are highly

subjective in nature. For fiscal year 2008, discrete tax benefits totaled

$8.3 million ($0.13 per share), $7.8 million ($0.12 per share) of which

was recognized in the third fiscal quarter, principally associated with

the release of valuation allowances on foreign tax credit carryforwards

and the recognition of certain previously unrecognized tax benefits

associated with recently completed tax audits. Discrete adjustments in the

prior year comparable periods were much less significant.

Selected Summary Balance Sheet Schedule

09/30/2008 06/30/2008

Assets

Current Ass
'/>"/>

SOURCE Hill-Rom Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
3. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
4. BMP Sunstone Reports Third Quarter 2008 Financial Results
5. Endocare Reports Financial Results for Third Quarter 2008
6. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
7. Isis Reports Financial Results and Highlights for Third Quarter of 2008
8. OncoGenex Reports Third Quarter Financial Results
9. American Oriental Bioengineering Reports Third Quarter 2008 Financial Results
10. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
11. Dendreon Reports Third Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... JERUSALEM, Israel, December 2 Ga...uating the preclinical (animal study) safety and,e...echnology from Weill,Cornell Medical College and G...t inherited anemias such as Cooley,s Anemia. ,,...logies to expand, ex vivo,populations of stem/pro...
(Date:12/2/2009)...TY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentar..., a global biopharmaceutical company focused on en... the U.S. Food and Drug Administration (FDA) has g...3K/Akt pathway inhibitor compound, perifosine (KRX...ultiple myeloma. Keryx Biopharmaceuticals, Inc. ("...
(Date:12/1/2009)... Dr. Kerry Solomon announced that he has joine... redesigned website at www.DrKerrySolomon.com , w...r. Solomon is a proven LASIK, lens implant, and ca...recognized for his substantial contributions to im... of Trusted LASIK Surgeons, which screens LASIK su...
(Date:12/1/2009)... YORK, Dec. 1 Reportlinker.com ann...ble in its catalogue: ,, Emerging Clinical Tri... the changing healthcare and regulatory environmen...rging-Clinical-Trial-Locations---Eastern-Europe-Ma...latory-environment.html ,, Over the last decad...
Breaking Biology Technology:Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8
...Dynamic Alert,Limited (OTC Bulletin Board: DYMC) i...ts target markets for its pharmaceutical product l... some capacity for enhancing rapid onset,through o...s lotions and,salves, and various products for int...while others may treat a range of problems. In kee...
...l experience with the FDA,cleared Visica 2(TM) Tre...fectiveness of ultrasound guided cryoablation to c...l Breast Cancer (IDC). Initial data from this,mul...ic Assembly and Annual,Meeting of the Radiological...cember 5, 2008. , The study, "New Findings o...
...enesco Technologies, Inc. ("Senesco" or the "Compa... its Development and License Agreement with the h...erminated by mutual agreement because of Harris Mo... , , Harris Moran has reported that its paren...eed operations and that Harris Moran will now be p...
Other Biology Technology:Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 3Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 2Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 3Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3
(Date:12/2/2009)... New York, NY, December 2, 2009 Commonly prescrib...nt of asthma in pregnant women as well as pre-term...um disorders, psychiatric pathology, cognitive pro...n, according to a new study published in the Decem...ics & Gynecology . , Beta 2 adrenergic agonist d...
(Date:12/1/2009)... Broadly speaking, ants have two different feeding...e "carnivorous," meaning that they are generalist ...ging on their remains. Some, however, are "herbiv...nts; rather, the bulk of their diets consist of pl...icky fluids produced by plants to attract ants, ca...
(Date:12/1/2009)... Particularly in Alzheimer,s disease, nerve cell d...ew therapeutic options may possibly be derived fro...sm. These findings have been published in the curr...ence . Until only a few years ago, neurogenesis t...ed to be impossible in the adult brain. The textbo...
Breaking Biology News(10 mins):Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2Bacterial gut symbionts are tightly linked with the evolution of herbivory in ants 2New source discovered for the generation of nerve cells in the brain 2Patterson Companies Expands Deployment of MicroStrategy for Enhanced Reporting and Analytics 52508 1Patterson Companies Expands Deployment of MicroStrategy for Enhanced Reporting and Analytics 52508 2Patterson Companies Expands Deployment of MicroStrategy for Enhanced Reporting and Analytics 52508 3Abaxis to Report First Quarter Fiscal 2010 Financial Results Thursday July 30 2009 52506 1Abaxis to Report First Quarter Fiscal 2010 Financial Results Thursday July 30 2009 52506 2Hisamitsu Pharmaceutical Co Inc Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals Inc 52504 1Hisamitsu Pharmaceutical Co Inc Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals Inc 52504 2
... people, but the disease can place a special burde...atients on chemotherapy. A five-year, $10.7 millio...adelphia will support research to determine how ad... be uniquely vulnerable to influenza, and will see... with compromised immune systems may be contagious...
...cently derived human gene trees by Alan R. Templet...ows three distinct major waves of human migration ...lly refutes –strongly ?the ,Out of Africa, replace...of Homo sapiens left Africa 100,000 years ago and ...on has shown that the African populations interbre...
...f Science, their lizard study describes how the "s...al, eye, distinguishes two different colors, blue ...alized nerve cells in that eye, which looks more l... of molecular signals to sense light: those found ...found only in more complex animals like humans. ,...
Other Biology News:How can we protect patients with weakened immune systems from influenza? 2How can we protect patients with weakened immune systems from influenza? 3New analysis shows three human migrations out of Africa 2Lizard 'third eye' sheds light on evolution of color vision 2
Silencer Pre-designed siRNA, HPLC purified, annealed from Ambion
...pidly and reliably amplify unknown genomic DNA us...hassle-free, ready-to use components, at an extrao...ents are provided in each kit. The Genome Walking ... of genomic DNA, isolating promoter and regulatory...
Rabbit Anti-Yaf9 Polyclonal Antibody, Unconjugated from Abcam
Bovine Calf Serum - 500mL from GeneTex
Biology Products: